PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: Can we afford it?

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.017 ◽

2015 ◽

Vol 137 ◽

pp. 9 ◽

Author(s):

H.J. Smith ◽

C.L. Walters Haygood ◽

R.C. Arend ◽

C.A. Leath ◽

J.M. Straughn

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Platinum Sensitive

Download Full-text

EP795 Searching for the best maintenance therapy in platinum-sensitive recurrent ovarian cancer: bevacizumab or PARP-inhibitors? A network meta-analysis

10.1136/ijgc-2019-esgo.846 ◽

2019 ◽

Author(s):

M Bartoletti ◽

G Pelizzari ◽

L Bortot ◽

M Giavarra ◽

MG Vitale ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Meta Analysis ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Platinum Sensitive

Download Full-text

A cost-effectiveness analysis of three PARP inhibitors for maintenance therapy in platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.027 ◽

2018 ◽

Vol 149 ◽

pp. 9 ◽

Author(s):

A.Y. Liu ◽

J.G. Cohen ◽

C. Walsh ◽

C.H. Holschneider ◽

A.K. Sinno

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Cost Effectiveness Analysis ◽

Platinum Sensitive ◽

Effectiveness Analysis

Download Full-text

A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.07.025 ◽

2017 ◽

Vol 147 (1) ◽

pp. 196 ◽

Author(s):

A.Y. Liu ◽

J.G. Cohen ◽

C.S. Walsh ◽

C.H. Holschneider ◽

A.K. Sinno

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Cost Effectiveness Analysis ◽

Platinum Sensitive ◽

Effectiveness Analysis

Download Full-text

PCN239 REAL WORLD AVERAGE DOSE OF PARP INHIBITORS USED AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE RECURRENT OVARIAN CANCER

Value in Health ◽

10.1016/j.jval.2020.04.1709 ◽

2020 ◽

Vol 23 ◽

pp. S65

Author(s):

J. Perhanidis ◽

P.H. Thaker ◽

A. McBride ◽

C. Hawkes

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Average Dose ◽

World Average ◽

Platinum Sensitive

Download Full-text

Comparison of PARP Inhibitors as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

10.37766/inplasy2021.6.0033 ◽

2021 ◽

Author(s):

Meng Wu ◽

HongMei Wang ◽

ZhengXiang Han

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Meta Analysis ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Platinum Sensitive

Download Full-text

Effects of PARP inhibitors therapy on the PFS and OS in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.630 ◽

2019 ◽

Vol 154 ◽

pp. 271

Author(s):

B.H. Min ◽

S.H. Yoon ◽

S.H. Shim

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Controlled Trials ◽

Randomized Controlled ◽

Platinum Sensitive

Download Full-text

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00681-8 ◽

2021 ◽

Vol 162 ◽

pp. S18

Author(s):

Qidan Huang ◽

Xiaohua Wu ◽

Jianqing Zhu ◽

Danqing Wang ◽

Jiaxin Yang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Subgroup Analysis ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Time To Progression ◽

Platinum Sensitive ◽

Platinum Based Chemotherapy

Download Full-text

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Download Full-text

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Annals of Oncology ◽

10.1093/annonc/mdy285.193 ◽

2018 ◽

Vol 29 ◽

pp. viii351-viii352

Author(s):

J.R. Gallagher ◽

K.J. Heap ◽

S. Carroll

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Observational Study ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Dose Cohort ◽

Platinum Sensitive ◽

Download Full-text

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.08.013 ◽

2015 ◽

Vol 139 (1) ◽

pp. 59-62 ◽

Author(s):

Haller J. Smith ◽

Christen L. Walters Haygood ◽

Rebecca C. Arend ◽

Charles A. Leath ◽

J. Michael Straughn

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Cost Effectiveness Analysis ◽

Platinum Sensitive ◽

Effectiveness Analysis

Download Full-text